Cancer researcher fabricated data in 30 papers — MD Anderson forced retirement

Bharat Aggarwal was an Indian-American biochemist who spent 26 years at the University of Texas MD Anderson Cancer Center, where he was a professor and led research on cytokines, inflammation, and the anti-cancer properties of curcumin. He was one of the most cited researchers in his field, publishing in top journals and bringing substantial grant revenue to the institution. His work was considered foundational to understanding how natural compounds might fight cancer.

In 2012, the U.S. Office of Research Integrity notified MD Anderson of whistleblower allegations that Aggarwal had fabricated or manipulated data in up to 65 of his published papers. The fraud involved reused and altered images presented as results from different experiments — bands in gel blots copied from one figure to another, images rotated and relabeled to represent different outcomes. MD Anderson launched an internal review that confirmed the allegations.

The retractions came in waves: 7 papers in Biochemical Pharmacology in February 2016, 2 in Molecular Pharmacology in June 2016, 9 in AACR journals in September 2018. By 2023, 30 papers had been retracted, 10 more received expressions of concern, and 17 were corrected. Aggarwal retired from MD Anderson on December 31, 2015, and was permanently barred from federal research funding. He threatened legal action against Retraction Watch in 2013 but never followed through.

MD Anderson waited for federal notification, then retracted 30 papers over a decade, forcing retirement and barring Aggarwal from federal funding.

Aggarwal was a star researcher who brought prestige and grants — MD Anderson had every incentive to minimize the damage rather than investigate aggressively.

The fraud was discovered by whistleblowers, not by the institution's own oversight — MD Anderson did not act until the federal government notified them.

The retraction process took more than a decade — the first retractions came in 2016, but new ones were still appearing in 2023, meaning the literature was poisoned for years.

Aggarwal threatened his critics rather than addressing the evidence — the Retraction Watch legal threat was an attempt to silence the disclosure of his misconduct.

When a star researcher brings in grants, the institution looks the other way. MD Anderson was notified of fraud in 2012 but Aggarwal retired in 2015 — the retractions kept coming for a decade.

The Aggarwal case was one of the largest research fraud cases in cancer biology. It highlighted how institutions protect their star researchers, even when federal investigators have already identified problems. The long tail of retractions — still appearing years after his retirement — meant that other researchers built on falsified data for years before the record was corrected. MD Anderson's reputation was damaged, and the case became a textbook example of the 'too big to fail' problem in academic research, where institutions prioritize grant revenue over scientific integrity.